Clinical Trial

Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a 2-part, proof-of-concept study to be conducted globally, designed to evaluate the safety, tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of BLU-808, a wild type KIT inhibitor, in participants with CIndU (Part A) or CSU (Part B).
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-23
Trial Details
NCT Number NCT06931405
Lead Sponsor Blueprint Medicines Corporation
Conditions Chronic Inducible Urticaria, Chronic Spontaneous Urticaria
Enrollment 105 participants
Start Date 2025-05-28
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-22